The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 1, 2009, Pages 83-89

  Chen, Chih Hsin ^a   Liu, Ya Chi ^b   Wu, Pei Chang ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE SURGERY; FEMALE; HUMAN; LENS IMPLANT; MALE; PHACOEMULSIFICATION; RETINA DETACHMENT; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; LENS IMPLANTATION, INTRAOCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; PHACOEMULSIFICATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 61749095294     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0068     Document Type: Article

References (41)

1. Gaudric, A., and Massin-Korobelnik, P. [Diabetic maculopathy: Classification, epidemiology, spontaneous outcome, treatment]. Diab. Metab. 19:422-429, 1993.
2. Bresnick, G.H. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 90:1301-1317, 1983.
3. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98:766-785, 1991.
4. Lee, C.M., and Olk, R.J. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 98:1594-1602, 1991.
5. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611, 2004.
6. Adamis, AP., Miller, JW., Bernal, M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol 118:445-450, 1994.
7. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994.
8. Malecaze, F., Clamens, S., Simorre-Pinatel, V., J. et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476-1482, 1994.
9. Tolentino, M.J., McLeod, D.S., Taomoto, M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol. 133:373-385, 2002.
10. Tolentino, M.J., Miller, J.W., Gragoudas, E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820-1828, 1996.
11. Cunningham, E.T., Jr., Adamis, A.P., Altaweel, M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747-1757, 2005.
12. Ferrara, N., Hillan, K.J., Gerber, H.P. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:391-400, 2004.
13. Yang, J.C., Haworth, L., Sherry, R.M., et al. A randomized trial of bevacizumab, an anti vascular endothelial growth factor antibody, for metastatic renal cancer. N. Eng.l J. Med. 349:427-434, 2003.
14. Marshall, J. The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol. 32:S43-S47, 2005.
15. Raftery, J., Clegg, A., Jones, J., et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br. J. Ophthalmol. 91:1244-1246, 2007.
16. Arevalo, J.F., Fromow-Guerra, J., Quiroz-Mercado, H., et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750, 2007.
17. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372 e365, 2006.
18. Byeon, S.H., Kwon, Y.A., Oh, H.S., et al. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J. Ocul. Pharmacol. Ther. 23:387-394, 2007.
19. Spaide, R.F. and Fisher, Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, 2006.
20. Hamilton. A.M.P., Ulbig, M.W., and Polkinghorne P. Epidemiology of diabetic retinopathy. In: Management of Diabetic Retinopathy. BMJ Publishing Group, London;, 996; 1-15
21. Squirrell, D., Bhola, R., Bush, J., et al. A prospective, case-controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br. J. Ophthalmol. 86:565-571, 2002.
22. Jonas, J.B., Spandau, U.H., Schlichtenbrede, F., et al. Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration. J. Ocul. Pharmacol. Ther. 23:599-600, 2007.
23. Hee, M.R., Puliafito, C.A., Wong, C., et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 113:1019-1029,1995.
24. Sanchez-Tocino, H., Alvarez-Vidal, A., Maldonado, M.J., et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest. Ophthalmol. Vis. Sci. 43:1588-1594, 2002.
25. Scott, I.U., Schein, O.D., West, S., et al. Functional status and quality-of-life measurement among ophthalmic patients. Arch. Ophthalmol 112:329-335, 1994.
26. Gomez-Ulla, F., Marticorena, J., Alfaro, D.V., 3rd, et al. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr. Diab. Rev. 2:99-112, 2006.
27. Audren, F., Lecleire-Collet, A., Erginay, A., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs. 2 mg. Am. J. Ophthalmol. 142:794-799, 2006.
28. Gillies, M.C., Sutter, F.K., Simpson, J.M., et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533-1538, 2006.
29. Jonas, J.B., Kreissig, I., and Degenring, R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 87:24-27, 2003.
30. Jonas, J.B., Degenring, R., Vossmerbauemer, U. et al. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur. J. Ophthalmol. 15:462-464, 2005.
31. Roth, D.B., Chieh, J., Spirn, M.J., et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch. Ophthalmol. 121:1279-1282, 2003.
32. Jonas, J.B., Kreissig, I., and Degenring, R.F. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch. Ophthalmol. 121:1663-1664, 2003.
33. Lam, D.S., Chan, C.K., Mohamed, S., et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot study. Eye 19:885-890, 2005.
34. Habib, M.S., Cannon, P.S. and Steel, D.H. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract. BMC Ophthalmol. 5:15, 2005.
35. Benhamou, N., Massin, P., Haouchine, B., et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am. J. Ophthalmol. 135:246-249, 2003.
36. Haritoglou, C., Kook, D., Neubauer, A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005, 2006.
37. Moshfeghi, D.M., Kaiser, P.K., Scott, I.U., et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. 136:791-796, 2003.
38. Phillips, W.B., 2nd, and Tasman, W.S. Postoperative endophthalmitis in association with diabetes mellitus. Ophthalmology 101:508-518, 1994.
39. Ray, S. and D'Amico, D.J. Pseudophakic cystoid macular edema. Semin. Ophthalmol. 17:167-180, 2002.
40. Mason, J.O., 3rd, Albert, M.A., Jr., and Vail, R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356-357, 2006.
41. Arevalo, J.F., Garcia-Amaris, R.A., Roca, J.A., et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group. J. Cataract Refract. Surg. 33:2098-2105, 2007.